Dr. Smogorzewska, who received her Ph.D. at Rockefeller University in 2002 under the tutelage of Titia de Lange, head of the Laboratory of Cell Biology and Genetics, and her M.D. from Weill Cornell Medical College in 2003, has devoted her career to examining pathways that prevent cancer development, specifically those that repair DNA and induce replicative senescence, a process by which cells terminally arrest growth.
“In the case of Fanconi anemia, patients are very susceptible to a very specific DNA damage that is created by cross-linking agents such as cisplatin,” says Dr. Smogorzewska. “I am interested in understanding how the DNA repair pathway in patients with Fanconi anemia works, the function of the proteins in that pathway and their contribution to cancer prevention.”
Dr. Smogorzewska honed her interest in molecular biology and biochemistry as an undergrad at the University of Southern California, where she also received a summer research scholarship in biological research sponsored by the Howard Hughes Medical Institute and a science and engineering research scholarship sponsored by the United States Department of Energy. After receiving her Ph.D and M.D. she did a clinical pathology residency at Massachusetts General Hospital, and then joined the genetics department at Harvard Medical School, where she has been a postdoc since 2005 in the laboratory of Stephen Elledge.
As a postdoc, Dr. Smogorzewska identified and characterized FANCI, a gene that is mutated in a subset of Fanconi anemia patients. Dr. Smogorzewska’s research further revealed that this gene affects the repair of DNA. Without the proper protein, DNA isn’t repaired and the outcome is full-blown Fanconi anemia, a genetic disorder characterized by bone marrow failure, skeletal anomalies and increased incidence of tumors. Dr. Smogorzewska also completed two whole-genome genetic screens using RNA interference in human cells, one that yielded a list of proteins necessary for survival after DNA cross-link damage and a second that resulted in a list of proteins important for induction of replicative senescence. Both screens identified many novel components of these critical cellular processes.
At Rockefeller, Dr. Smogorzewska will focus her research on understanding how several of these proteins regulate the activity of the Fanconi anemia pathway and other pathways necessary for DNA repair, and on identifying factors that promote survival in Fanconi anemia cells in the setting of DNA damage.
“When a cell is confronted with DNA damage, it can either try to repair the genome or, in the case of irreparable damage, trigger cell death or senescence,” says Dr. Smogorzewska. “My focus is on how the cell tries to repair itself in order to survive and on processes that are induced when the proper repair fails.”
“I am delighted that Agata will be joining the university’s faculty,” says Paul Nurse, the university’s president. “Her research will shed light on the complex processes by which cells detect and repair damaged DNA — processes that have important implications for understanding cancer — and has the potential to help patients with genetic disorders.”
Thania Benios | Newswise Science News
The birth of a new protein
20.10.2017 | University of Arizona
Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Information Technology
20.10.2017 | Materials Sciences
20.10.2017 | Interdisciplinary Research